Increased TPX2 nuclear expression identified by IHC can enable the identification of breast cancers with poor clinical behavior, elevated proliferative rate, high incidence of pathologic TP53 mutations, and greater genomic complexity. The gene discussed is TP53; the disease is breast carcinoma.